Project Grant R01AR084831
Award Date
9/24/24
Completion Date
7/31/29
Dollars Obligated
$829K
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
This $506,085 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to identify predictive biomarkers for response to biological therapies in patients with rheumatoid arthritis (RA). The primary focus is on evaluating the potential of obesity-induced inflammatory mediators, including proteins (adipokines) and lipids, to predict...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a novel joint-targeted antibody therapy for the treatment of rheumatoid arthritis (RA). The award, totaling $402,086, will support the research team's efforts to synthesize new collagen hybridizing peptide (CHP) structures with high affinity to denatured collagen, and to...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $170,101 to Brigham & Women's Hospital Inc. from January 1, 2025 to December 31, 2029. The award supports research to characterize the spatial heterogeneity of synovial inflammation in rheumatoid arthritis (RA). The project aims to 1) identify the spatial underpinnings of known RA...
This $358,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research at Brigham & Women's Hospital to elucidate social determinants of health and mental health needs in order to achieve equity in rheumatic disease care. The award will fund a 2-year study that leverages data from the All of Us research program to: Assess the effects of...
This federal Project Grant award, totaling $735,372, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports research to investigate the extrinsic signals and transcription factors that induce the expression of inflammatory chemokine receptors, such as CCR2, CCR5, and CXCR6, on T cells in chronic autoimmune conditions like rheumatoid arthritis. The...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $529,616 Project Grant (R01AR085028) to Brigham & Women's Hospital Inc. for the period of June 1, 2025 to May 31, 2030. The grant supports research to define the role of Notch signaling-driven fibrogenesis in treatment failure for rheumatoid arthritis (RA). The key objectives are to: 1) elucidate the molecular mechanism by which Notch regulates TGF-β signaling and fibrogenic programs in synovial...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $783,176 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Mayo Clinic. The purpose of this 2-year grant, effective September 20, 2024, is to develop and validate a quantitative spine imaging methodology using photon-counting detector computed tomography (PCD-CT) to comprehensively characterize bone quality in the vertebrae of patients undergoing...